Next Upcoming Seminar: FDA Nutrition Labeling Facts and Impacts on Food Label Claims – July 13, 2017

Specializing in FDA Regulatory Matters

Generally Recognized as Safe (GRAS) Notification Submissions

EAS Consulting Group, LLC. is an industry leader in submitting GRAS Notices to FDA for review.

GRAS Notification – No Objections

Below is a partial list of GRAS Notices EAS has submitted on behalf of its clients that have received “no objections” letters from FDA:

  • GRN 545 – Phosphatidylserine derived from sunflower
  • GRN 470 – Ethyl cellulose
  • GRN 413 – Beta glucans derived from Ganoderma lucidum mycelium
  • GRN 411 – Egg yolk-derived phospholipids
  • GRN 343 – Wheat bran extract composed primarily of xylo- and arabinoxylo-oligosaccharides
  • GRN 311 – Krill-based phosphatidylserine
  • GRN 294 – Haematococcus pluvialis extract containing astaxanthin esters
  • GRN 279 – Phosphatidylserine derived from fish
  • GRN 237 – Alkyl polyglycosides
  • GRN 226 – Lecithin derived from krill
  • GRN 223 – Phosphatidylserine
  • GRN 218 – Bacteriophage P100 preparation from Listeria innocua

GRAS Notification Prior to 2006

In addition, AAC Consulting Group, LLC., which was acquired by EAS Consulting Group in October 2006, successfully submitted the following GRAS notifications with no objections:

  • GRN 202 – Polyoxyethanyl-alpha-tocopheryl sebacate (PTS)
  • GRN 200 – Tailored triglycerides enriched in omega-3 fatty acids from fish oil
  • GRN 198 – Bacteriophage P100 preparation from Listeria innocua
  • GRN 152 – Sodium iron EDTA
  • GRN 135 – ε-Polylysine
  • GRN 27 – Dextranase from Chaetomium gracile

Also, EAS/AAC have helped numerous other firms documented the safety of ingredients through Independent (self) GRAS determinations and have helped firms submit GRAS Notices directly to FDA under their own company names.